Genelux公司:在晚期或转移性复发性非小细胞肺癌中,初始剂量组观察到抗肿瘤活性,Olvi-Vec总体耐受性良好(二期VIRO-25研究)

美股速递
Jan 05

Genelux Corporation宣布,其针对晚期或转移性复发性非小细胞肺癌(NSCLC)的二期VIRO-25临床研究取得积极进展。初步数据显示,在研究的初始剂量组中,已观察到抗肿瘤活性。同时,候选药物Olvi-Vec在患者中表现出良好的总体耐受性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10